PRS54 Recent Trends In Anaphylaxis-Related Hospitalization In The United States  by Candrilli, S & Kurosky, SK
 VA L U E  I N  H E A LT H  1 8  ( 2 0 1 5 )  A 3 3 5 – A 7 6 6  A503
those without on PCS and SF-6D, but not MCS. This suggests that SF-12v2 can aid 
in quantifying HRQL benefits from interventions that may reduce ER/hospital uti-
lization in adults with CF.
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Objectives: The Assessment of Burden of COPD (ABC) tool evaluates and visualizes 
the health status of patients with chronic obstructive pulmonary disease (COPD). 
This tool may be used during consultations to monitor the burden of COPD and to 
adjust treatment. The ABC tool has items in 5 dimensions: symptoms, limitations, 
mental status, exacerbations, and fatigue. The aim of our study was to determine 
the burden of each of 15 elements in the ABC questionnaire. MethOds: A discrete 
choice experiment (DCE) was conducted using telephone-assisted personal inter-
views with 279 COPD patients. They were presented 13 sets of two patients, and 
decided which patient was in the worst health state. In order to make the choice 
task feasible despite the large number of 15 attributes, we generated an efficient 
partial profile design, that kept attributes in some dimensions constant and all at 
the same level (fold in), while varying the attributes in other dimensions (fold out). 
This reduced the burden on respondents by having them assess some attributes 
combined in categories, instead of as separate attributes. Multinomial logit was 
used to analyze the data. Results: Patients were considered to be in worst health 
if they had high levels of fatigue, exacerbations, anxiety, breathlessness at rest and 
limitations in moderate physical activities. These factors had three to five times 
as much impact on the burden of disease as lower levels of these attributes and 
other limitations. Coefficients were very small and/or statistically insignificant for 
breathlessness during physical activity, limitations on strenuous activity, coughing, 
small numbers of exacerbations, and most mental attributes. cOnclusiOns: It is 
possible to administer cognitively complicated DCE questionnaires using a fold-in-
fold-out design. COPD-patients seem to accept being unable to perform strenuous 
activities. Gains in well-being can primarily be achieved by focusing on patients’ 
ability to lead a relatively normal everyday life.
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Objectives: Idiopathic pulmonary fibrosis (IPF) is a rare and fatal lung disease. 
EQ-5D utilities, an important consideration for cost-effectiveness analysis, are 
not commonly reported in IPF clinical trials. On the other hand, the St George’s 
Respiratory Questionnaire (SGRQ) is the most extensively used patient reported 
outcome measure in IPF patients. The objective of this study was to develop a 
mapping algorithm from the total SGRQ score to obtain EQ-5D utilities. MethOds: 
Data were analysed from a double-blind multicentre study conducted in England 
and Wales of which 181 IPF patients received either co-trimoxazole or placebo. 
In total, 202 pairs of data were collected recording both SGRQ and the EQ-5D-3L. 
Generalised mixed models, accounting for repeated measurements within 
subjects as residual or generalised random effects, were fit to the data. Explanatory 
variables were evaluated to aid model fit: Age; BMI; Sex; Forced Expiratory Volume 
in 1 second (FEV1); Forced Vital Capacity (FVC); and FEV1/FVC. Additionally, the 
potential non linearity of the relationship between explanatory and response 
variables was explored by investigating transformations and fitting restricted 
cubic splines with 4 knot points. Goodness of fit statistics determined the best 
fitting model. Results: The generalised random effects model was the best fit-
ting model. The addition of explanatory variables, use of transformations and 
investigation of a restricted cubic spline did not improve model fit. The final map-
ping algorithm, EQ-5D = 1.3246 – 0.01276*SGRQ, was associated with a root mean 
squared error of 0.1391. Inspection of the scatter plot showed that EQ-5D utili-
ties predicted by the mapping algorithm closely approximated observed values 
from the study. cOnclusiOns: A mapping algorithm was developed to estimate 
EQ-5D utilities from the total SGRQ score in IPF patients. This may be useful for 
researchers conducting cost-effectiveness analysis when EQ-5D utilities are not 
available from IPF clinical trials.
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Objectives: Chronic obstructive pulmonary disease (COPD) is one of the most 
common and burdensome chronic respiratory diseases. This pilot study aimed 
to explore the priorities of patients with moderate-to-severe COPD in relation 
to treatment. MethOds: Interviews were conducted with 20 patients with self-
reported moderate-to-severe COPD. Patients completed a brief best-worst scaling 
(BWS) exercise comprising 12 questions in which 15 features (benefits, harms, 
or administration features of a COPD treatment) were presented in sets of 5. On 
each question, patients indicated the most important and the least important 
feature when choosing whether to take a treatment. Frequency counts of features 
selected as the most or least important were used to generate BWS weights for 
each feature. BWS weights ranged from –1 to +1, with a positive weight reflecting 
greater importance. Results: The sample consisted of 11 males and 9 females, 
whose age range was 48 to 86 years (median: 65 years). BWS weights showed that 
the most important features were improved ability to perform daily activities 
Objectives: Patients with allergic asthma not well controlled on pharmacotherapy 
constitute a significant cost to society, whilst having reduced quality of life. Allergy 
immunotherapy tablets for sublingual administration (SLIT-tablets) have been devel-
oped as an effective, well tolerated and convenient treatment modality, suitable for 
home treatment. The purpose of this analysis was to investigate cost-effectiveness 
of the SQ® HDM SLIT-tablet in a population with allergic asthma that is not well 
controlled, despite use of pharmacotherapy. MethOds: A multicentre, double-
blind, randomised, placebo-controlled clinical trial with the SQ® HDM SLIT-tablet 
(ClinicalTrials.gov: NCT01433523) has shown statistically significant improvements 
for all efficacy endpoints in allergic asthma, including improvement in health-
related quality of life. A cost-utility analysis was performed using a decision tree 
structure and data taken from the SQ® HDM SLIT-tablet clinical trial, including 
SF-36 and health care utilisation data. Long-term efficacy data was limited, and 
therefore conservative assumptions were adopted, framed by expert advice. As basis 
for the analysis, German preference weights and costs were applied and a 9-year 
time horizon adopted. Uncertainty around efficacy assumptions was explored by 
sensitivity analyses. Results: The SQ® HDM SLIT-tablet was cost-effective com-
pared with pharmacotherapy, in the treatment of allergic asthma (ICER< 15,000 € /
QALY). During sensitivity analysis, model results were sensitive to changes in input 
parameters, particularly in relation to long-term effectiveness. This indicates the 
importance of establishing long-term outcomes following treatment with the SQ® 
HDM SLIT-tablet. cOnclusiOns: In the base case analysis, SQ® HDM SLIT-tablet 
proved to be cost-effective in the treatment of allergic asthma, compared to placebo. 
Conservative efficacy assumptions were adopted for the analysis, and therefore, the 
true benefits of the treatment may be underestimated.
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Objectives: Anaphylaxis is a severe, often life-threatening, allergic reaction (com-
monly to foods, insect stings, and medications), frequently requiring immediate 
medical attention. This study examined recent trends of anaphylaxis-related hos-
pitalization in the United States (US). MethOds: Study data were drawn from the 
Healthcare Cost and Utilization Project’s 2001-2012 National (Nationwide) Inpatient 
Samples (NIS), a nationally representative database of hospital discharges in the 
US. Anaphylaxis-related hospitalizations were identified using a modification 
of a previously published algorithm (Walsh et al, 2013); this algorithm evaluates 
diagnosis codes on each record to identify anaphylaxis-related hospitalizations. 
In addition to quantifying the rate of hospitalization (per 100,000 US population), 
length of stay (LOS) and total costs for such hospitalizations were evaluated. Overall 
estimates, as well as by age group, were generated. Results: Across all age groups, 
the rate of anaphylaxis-related hospitalizations increased by ~62% between 2001 
and 2012, from 2.4/100,000 US population in 2001 to 3.8/100,000 in 2012. In gen-
eral, annually the greatest rate was among those 65-84 years old, although the 
greatest rate observed was for those 85+ years in 2012, at 8.0/100,000, with rates 
among this age group steadily increasing over time. Among all anaphylaxis-related 
hospitalizations, the mean total cost (in 2014 US dollars) increased by more than 
55%, from $12,508 in 2001 to $19,420 in 2012. The mean LOS across all anaphylaxis-
related hospitalizations increased by > 1 full day, from 3.7 days in 2001 to 4.9 days 
in 2012. cOnclusiOns: Since the early 2000s, rates of anaphylaxis-related hospi-
talization in the US have increased, with the mean LOS and cost per stay increasing 
as well. Healthcare decision makers should be aware of these data as they plan for 
allocation of resources used to treat anaphylaxis.
ReSPiRAtoRy-RelAted diSoRdeRS – Patient-Reported outcomes & Patient 
Preference Studies
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Objectives: Compare generic health-related quality of life (HRQL) between adults 
with and without cystic fibrosis (CF) to assess disease burden and to evaluate 
whether HRQL varies by level of health resource utilization (HRU) among adults with 
CF. MethOds: Analysis sample included adult respondents to the 2013 National 
Health and Wellness Survey from the EU5 countries (France, Germany, Italy, Spain 
and UK) and the US. We measured HRQL using the Short Form (SF)-12v2 and its 
derived utility index, the SF-6D; we measured HRU using self-reported frequency of 
hospital/emergency room (ER) visits over the preceding 6 months. Analysis of vari-
ance models compared mean HRQL scores of CF versus non-CF respondents (non-
CF mean scores were weighted to match the CF group’s age and sex distributions). 
Mann-Whitney tests assessed differences in HRQL between CF respondents with 
0 (No ER/Hospitalization) versus ≥ 1 ER/hospital visits (Any ER/Hospitalization). We 
calculated Cohen’s d effect sizes (ES) to describe the magnitude of between-group 
differences in mean HRQL scores. Results: Seventy-nine of 75,000 US and 109 
of 62,000 EU5 respondents self-reported CF. Mean scores were lower for CF versus 
non-CF respondents for all HQRL domains (P< 0.001); differences in physical (PCS) 
and mental component summaries (MCS) and SF-6D scores had ES of 0.66, 0.55, 
and 0.77, respectively. Mean scores of CF respondents with Any ER/Hospitalization 
were lower than mean scores of CF respondents with No ER/Hospitalization for 
PCS (P< 0.001; ES= 0.67) and SF-6D (P< 0.001; ES= 0.58), while MCS scores were com-
parable (P= 0.713; ES= 0.16). cOnclusiOns: Results indicate a substantial burden 
of CF disease on both mental and physical HRQL. Furthermore, within adults with 
CF the SF-12v2 can discriminate between those with ER/hospital utilization versus 
